The treatment armamentarium of mCRPC has significantly evolved with the addition of hormonal agents such as Zytiga (Johnson & Johnson/Janssen) and Xtandi (Medivation/Astellas Pharma). These targeted therapies have benefited efficacy outcome and offer favorable safety profiles. The management of mCRPC has been further transformed with the availability of therapeutic vaccine Provenge (Valeant) and radiopharmaceutical agent Xofigo (Bayer HealthCare). Nevertheless, an enormous unmet need exists for better-tolerated novel therapies that could prolong overall survival and, to a greater extent, delay disease progression. Our unmet need module analyzes the key drivers of prescribing and identifies the most attractive commercial opportunities for drug developers.
Unmet Need provides quantitative insight into U.S. and European physicians’ perception of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, France, Germany, and the United Kingdom.
Primary research: Survey of 61 U.S. and 31 European medical oncologists fielded in August 2018.
Key companies: Johnson & Johnson/Janssen, Medivation/Astellas, Valeant, Bayer HealthCare, and Sanofi.
Key drugs: Zytiga, Xtandi, Provenge, Xofigo, and Jevtana.